Human VIP-alpha: an emerging biologic response modifier to treat primary pulmonary hypertension.
about
Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review.Emerging treatments for pulmonary arterial hypertension.Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease.Advances in therapies for pediatric pulmonary arterial hypertension.
P2860
Human VIP-alpha: an emerging biologic response modifier to treat primary pulmonary hypertension.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Human VIP-alpha: an emerging b ...... rimary pulmonary hypertension.
@ast
Human VIP-alpha: an emerging b ...... rimary pulmonary hypertension.
@en
type
label
Human VIP-alpha: an emerging b ...... rimary pulmonary hypertension.
@ast
Human VIP-alpha: an emerging b ...... rimary pulmonary hypertension.
@en
prefLabel
Human VIP-alpha: an emerging b ...... rimary pulmonary hypertension.
@ast
Human VIP-alpha: an emerging b ...... rimary pulmonary hypertension.
@en
P2860
P356
P1476
Human VIP-alpha: an emerging b ...... rimary pulmonary hypertension.
@en
P2093
Israel Rubinstein
P2860
P304
P356
10.1586/14779072.3.4.565
P577
2005-07-01T00:00:00Z